AbbVie (ABBV) Payables (2012 - 2026)

AbbVie (ABBV) has reported Payables for 15 consecutive years, with $33.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 11.9% year-over-year to $33.3 billion in Q2 2026; TTM through Jun 2026 was $33.3 billion, a 11.9% decrease from a year earlier, with the FY2025 full-year figure at $37.2 billion, up 16.55% from the prior year.
• Payables was $33.3 billion for Q2 2026 at AbbVie, down from $33.8 billion in the prior quarter.
• Over five years, Payables peaked at $37.8 billion in Q2 2025 and troughed at $22.6 billion in Q2 2022.
• A 5-year average of $30.1 billion and a median of $30.6 billion in 2023 frame the typical range for Payables.
• Across the five-year window, Payables advanced 28.89% in 2025 and retreated 11.9% in 2026, its largest moves.
• Over 5 years, Payables stood at $25.4 billion in 2022, then grew by 20.66% to $30.6 billion in 2023, then grew by 4.23% to $31.9 billion in 2024, then grew by 16.55% to $37.2 billion in 2025, then decreased by 10.56% to $33.3 billion in 2026.
• The last three Payables figures came in at $33.3 billion (Q2 2026), $33.8 billion (Q1 2026), and $37.2 billion (Q4 2025), per Business Quant data.